# Inside Tx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inside-tx

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.insidetx.com
- Total disclosed funding: $1.4M
- Latest round: Seed (May 29, 2024)
- Investors on record: 1

## About

Inside Therapeutics is a France-based company developing innovative solutions for biopharmaceutical formulation, specializing in RNA lipid nanoparticle technologies that enhance drug development processes.Inside Therapeutics was founded in 2022 in Paris, France, focusing on the advancement of nanoparticle and RNA-LNP formulations. The company was created by founders Audrey Nsamela and Robin Oliveres, with Thomas Guerinier serving as CEO. Inside Therapeutics has completed one significant funding event, raising EUR 1.304 million during its Seed round on May 29, 2024, led by Newfund Management with additional participation from other investors. The total amount raised by the company stands at EUR 1.304 million, with a current valuation of EUR 4.754 million.Inside Therapeutics specializes in the manufacturing of nanoparticles and RNA lipid nanoparticle (RNA-LNP) formulations. Their flagship product, the TAMARA system, enables rapid formulation of complex biopharmaceuticals in under ten seconds through a straightforward three-step process. This system is designed to assist pharmaceutical and biotechnology companies in drug development, facilitating transitions from discovery to in vivo testing while maintaining material efficiency and quality. Clients include organizations such as OSE Immunotherapeutics, which utilize Inside Therapeutics' technology to improve their RNA-LNP synthesis processes. The company services a global market, focusing primarily on North America, Europe, and Asia.Inside Therapeutics operates on a direct B2B transaction model, providing the TAMARA system along with tailored training packages to meet specific research and development needs. The revenue structure comprises initial sales of the TAMARA system and recurring income generated from training and support services aimed at optimizing the use of their technology in drug development. The company emphasizes high-value partnerships with pharmaceutical and biotech firms to enhance their clients' capabilities in the field of nanomedicine.In May 2024, Inside Therapeutics successfully raised EUR 1.3 million in Seed funding to propel the development of its candidate RNA therapies, strengthen its market presence, and expand its team. The funding will facilitate the design and launch of upcoming products geared towards enhancing the efficiency of RNA therapies. Additionally, the company is looking to broaden its reach into new markets, specifically targeting expansions into Asia and North America by late 2024.

## Funding rounds

- Seed, May 29, 2024, $1.4M — Newfund

## Investors

- Newfund (https://capitalatlas.ai/funds/newfund) — Seed